Navigation Links
ADVENTRX Announces Establishment of Regulatory Advisory Board
Date:4/9/2012

SAN DIEGO, April 9, 2012 /PRNewswire/ -- ADVENTRX Pharmaceuticals, Inc. (NYSE Amex: ANX) today announced the establishment of a Regulatory Advisory Board (RAB). The RAB will provide drug development and regulatory affairs guidance to Company management in its interactions with the U.S. Food and Drug Administration (FDA).  Frank J. Sasinowski, M.S., M.P.H., JD, who is rendering legal advice to Company management, and in that capacity also will advise the RAB, is a Director at Hyman, Phelps & McNamara, P.C., a law firm with one of the most extensive food and drug practices in the United States, and a current At Large member and a former Chair of the Board of Directors of the National Organization for Rare Disorders (NORD). 

"As a Director of NORD, I have worked closely with the rare disease community, as well as lawmakers, to raise awareness for the over 7,000 rare diseases that affect nearly 30 million Americans," stated Mr. Sasinowski. "I believe that ANX-188 has significant potential to ease the suffering of patients with sickle cell disease.  I look forward to advising the Company as it develops this important new product candidate."  

"Our ability to attract these experienced industry veterans reflects favorably on the potential of ANX-188," stated Brian M. Culley, Chief Executive Officer of ADVENTRX. "The establishment of this RAB also highlights our commitment to frequent and open communication with the Agency.  We look forward to advancing ANX-188 into a phase 3 clinical trial later this year, and bringing the hope of a new therapy for sickle cell patients one step closer to fruition."

Frank J. Sasinowski, M.S., M.P.H., JD

In his practice at Hyman, Phelps & McNamara, P.C., Mr. Sasinowski assists sponsors in developing new medicines and has helped secure FDA approval for hundreds of new drugs including more th
'/>"/>

SOURCE ADVENTRX Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. ADVENTRX Announces Appointment of Senior Vice President, Commercial
2. ADVENTRX Pharmaceuticals Reports Second Quarter Financial Results
3. ADVENTRX to Hold Second Quarter Results and Business Update Conference Call on August 12
4. ADVENTRX Pharmaceuticals Announces Financing
5. ADVENTRX Pharmaceuticals Announces Plans for Remainder of 2009
6. ADVENTRX Pharmaceuticals Announces Closing of Financing
7. ADVENTRX Pharmaceuticals Announces Financing
8. ADVENTRX Pharmaceuticals, Inc. Reports Fourth Quarter and Full Year 2008 Financial Results
9. ADVENTRX Announces Further Cost-Cutting Measures
10. ADVENTRX Provides Update on Strategic Transaction Process
11. ADVENTRX Announces Further Cost-Cutting Measures
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2015)... May 4, 2015  Soligenix, Inc. (OTCQB: SNGX) (Soligenix ... that address unmet medical needs in the areas of ... be presenting preclinical data from three of its biodefense ... and Technology Conference on May 12-14, 2015 to be ... Convention Plaza, St. Louis MO ...
(Date:5/4/2015)... WASHINGTON , May 4, 2015   ... announced updated interim data from Tocagen,s ongoing investigational ... Satellite Symposium of the American Association of Neurological ... Tumors, held May 1-2, 2015, in ... the company held a meeting with FDA and ...
(Date:5/4/2015)... 04, 2015 Marianjoy Rehabilitation ... with arm and hand impairments by acquiring the ... Oakbrook Terrace network site. , Secured through grant ... a highly-regarded treatment option for patients with upper ... Marianjoy becomes one of just four Illinois providers ...
(Date:5/1/2015)... MINNEAPOLIS, MN , May 1, 2015 /PRNewswire/ - ... company producing sustainable chemicals, today announced that it has priced ... common stock at a price of $9.00 per share, ... option to purchase up to an additional 585,000 shares ... Company will be $35.1 million.  The offering is expected to ...
Breaking Biology Technology:Soligenix Announces Presentation and Poster at the 2015 Chemical and Biological Defense Science and Technology Conference in St. Louis, MO 2Soligenix Announces Presentation and Poster at the 2015 Chemical and Biological Defense Science and Technology Conference in St. Louis, MO 3Soligenix Announces Presentation and Poster at the 2015 Chemical and Biological Defense Science and Technology Conference in St. Louis, MO 4Soligenix Announces Presentation and Poster at the 2015 Chemical and Biological Defense Science and Technology Conference in St. Louis, MO 5Soligenix Announces Presentation and Poster at the 2015 Chemical and Biological Defense Science and Technology Conference in St. Louis, MO 6Soligenix Announces Presentation and Poster at the 2015 Chemical and Biological Defense Science and Technology Conference in St. Louis, MO 7Soligenix Announces Presentation and Poster at the 2015 Chemical and Biological Defense Science and Technology Conference in St. Louis, MO 8Soligenix Announces Presentation and Poster at the 2015 Chemical and Biological Defense Science and Technology Conference in St. Louis, MO 9Soligenix Announces Presentation and Poster at the 2015 Chemical and Biological Defense Science and Technology Conference in St. Louis, MO 10Soligenix Announces Presentation and Poster at the 2015 Chemical and Biological Defense Science and Technology Conference in St. Louis, MO 11Soligenix Announces Presentation and Poster at the 2015 Chemical and Biological Defense Science and Technology Conference in St. Louis, MO 12Tocagen Presents Updated Interim Survival Data from Ongoing Clinical Studies at American Association of Neurological Surgeons (AANS)/Congress of Neurological Surgeons (CNS) Section on Tumors 2Tocagen Presents Updated Interim Survival Data from Ongoing Clinical Studies at American Association of Neurological Surgeons (AANS)/Congress of Neurological Surgeons (CNS) Section on Tumors 3Tocagen Presents Updated Interim Survival Data from Ongoing Clinical Studies at American Association of Neurological Surgeons (AANS)/Congress of Neurological Surgeons (CNS) Section on Tumors 4Tocagen Presents Updated Interim Survival Data from Ongoing Clinical Studies at American Association of Neurological Surgeons (AANS)/Congress of Neurological Surgeons (CNS) Section on Tumors 5Marianjoy Acquires Armeo®Spring Arm and Hand Rehabilitation Exoskeleton at Oakbrook Terrace Facility 2BioAmber Inc. Announces Pricing Of $35.1 Million Registered Offering 2BioAmber Inc. Announces Pricing Of $35.1 Million Registered Offering 3
... has released a new medical imaging product for ... reading capabilities of radiologists. , ,According to Merge, the ... make possible simultaneous display and reading of images on ... which vendor's acquisition device is used to secure the ...
... Wis. - GE Healthcare has signed ... Excellence in Breast Cancer Imaging within the University ... ,With funding from GE Healthcare, a $17 billion unit ... designed to advance and commercialize research and technology to ...
... - CIOs must know something that Alan Greenspan doesn't ... mode in the second quarter of 2007, according to the ... hiring. , ,The report, published after former Federal Reserve ... the second half of the year, indicates that 14 percent ...
Cached Biology Technology:
(Date:3/24/2015)... , March 24, 2015   NexID Biometrics ... with critical security-authentication needs, today announced the beginning of ... (FFD) solution. The company, based in ... at the three-day Connect:ID Expo, which began here today ... NexID said version 2.0 of its SDK boosts the ...
(Date:3/23/2015)... March 23, 2015  In the 2014 fiscal year, ... conviction losses. This figure accounts for a fraction of ... The Nilson Report, exceeds $11 billion globally. The polygraph ... a crime has occurred. Investor Mark Saint Juste ... Joe Paolella partnered to administer the test ...
(Date:3/20/2015)... NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" ... the growing mobile commerce market, announces its biometric payment ... products featured in 2015 "I Want That" International CES ... on the DIY Network.   DIY,s "I ... , site of the 2015 International CES for a ...
Breaking Biology News(10 mins):NexID Begins Shipments Of Version 2.0 Fake-Finger-Detection Solution 2Polygraph Test Now Used to Protect Investors From Fraud 2Polygraph Test Now Used to Protect Investors From Fraud 3NXT-ID's Wocket Biometric Smart Wallet to Air on "I Want That" International CES Special 2NXT-ID's Wocket Biometric Smart Wallet to Air on "I Want That" International CES Special 3
... the University of Illinois have developed a new model ... transform the understanding of how plants and soils interact ... model takes into account the role of nitrogen dynamics ... change and rising atmospheric carbon dioxide. Current models ...
... (Dec. 11, 2007) A new study comparing the ... actual climate data finds that the models do an ... of the atmosphere. This research, published on-line Wednesday ... raises new concerns about the reliability of models used ...
... climate negotiations proceed in Bali, Indonesia, researchers have taken ... different countries to future climate change. The research ... Centre for Theoretical Physics in Trieste, Italy, found that ... gas-emitting nations that are currently unbound by the Kyoto ...
Cached Biology News:New model revises estimates of terrestrial carbon dioxide uptake 2New model revises estimates of terrestrial carbon dioxide uptake 3New study increases concerns about climate model reliability 2New study increases concerns about climate model reliability 3Scientists develop new measure of 'socioclimactic' risk 2Scientists develop new measure of 'socioclimactic' risk 3Scientists develop new measure of 'socioclimactic' risk 4
... The MONOLIGHT 3096 Microplate Luminometer ... chemi- and bioluminescence and for,all measurements ... microplates,i.e. for reactions where the light ... of time, as well as for ...
... new Adept CE 4100 high pressure ... flow precision, with software drive compensation, reducing ... 0.001-10mL/min are selectable in 0.001mL steps. , ... inert and bio-compatible., Pumps may be programmed ...
High affinity antibodies recognizes HSP70 protein from human cardiac tissue. Could be used for Westerb blotting application, ELISA....
Recommended for use as a cell culture substratum at 0.1-0.2 mg/cm 2 or 5-10 μl/cm 2 . Optimal concentration depends on cell type as well as the application or research objectives. Type B...
Biology Products: